Number of the records: 1  

Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European drug-induced liver injury network [PRO-EURO-DILI-NET]

  1. 1.
    0546144 - FZÚ 2022 RIV NL eng J - Journal Article
    Fernandez-Checa, J.C. - Bagnaninchi, P. - Ye, H. - Sancho-Bru, P. - Falcon-Perez, J.M. - Royo, F. - Garcia-Ruiz, C. - Konu, O. - Miranda, J. - Lunov, Oleg - Dejneka, Alexandr - Elfick, A. - McDonald, A. - Sullivan, G.J. - Aithal, G.P. - Lucena, M.I. - Andrade, R.J. - Fromenty, B. - Kranendonk, M. - Cubero, F.J. - Nelson, L.J.
    Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European drug-induced liver injury network [PRO-EURO-DILI-NET].
    Journal of Hepatology. Roč. 75, č. 4 (2021), s. 935-959. ISSN 0168-8278. E-ISSN 1600-0641
    R&D Projects: GA MŠMT LTC19040
    Institutional support: RVO:68378271
    Keywords : acetaminophen * iPSCs * liver-on-a-chip * humanized models
    OECD category: Biochemistry and molecular biology
    Impact factor: 30.083, year: 2021
    Method of publishing: Open access

    Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing.
    Permanent Link: http://hdl.handle.net/11104/0322792

     
    FileDownloadSizeCommentaryVersionAccess
    0546144.pdf14.3 MBCC licencePublisher’s postprintopen-access
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.